About Us

Granman Biotech focuses on providing high-throughput cell editing solutions to serve new drug research and development and basic scientific research.

Granman Biotech is a technology-driven company focusing on the research and development of high-throughput cell editing tools, the core technology from the University of California, Berkeley, the company has completed the knockout experiment verification of 19,883 genes in the whole human genome. Based on the intelligent high-throughput in vitro cell editing platform of Granman, it provides customers with a series of products such as gene knockout, overexpression, point mutagenesis, in situ/site-directed knock-in customized services, gene editing cell spots, gene knockout kits, etc., to help new drug research and development and basic research.

As a benchmark enterprise in the field of high-throughput gene knockout array libraries in China, Grainman has built an automated and high-throughput gene knockout platform to achieve a production capacity of 1000+ KO cells per month. Based on the self-constructed Harbor cell and pCargo plasmid vector system, Granman achieves efficient construction of stable cell lines in 2 weeks.

关闭视频

Automated, High-Throughput Gene Knockout

关闭视频

High Throughput Automated PCR

22000 + Gene Knockout Experience
67000 + Number of knockout products
2000 + Short-term delivery of KO cell capacity
70 % More than 70% of the knockout efficiency

Development Process

2024

The company completed its angel round of financing, establishing a 1000+ square meter P2 laboratory, serving hundreds of pharmaceutical companies and scientific research clients

2023

The company has completed the construction of more than 150 drug target report cell lines (Harbor cells), and Liman has deeply deployed cell line-related products in the field of protein degradation drugs (TPD).

2022

The company has established an automated, high-throughput gene knockout production platform, achieving a production capacity of 400+ highly efficient KO cells per month; the company has also established a high-throughput cloning platform, achieving the construction of 1000+ plasmid vectors per month

News

The latest information, technical training activities and conference developments of Elem Biotech.

Elem Biology has established long-term cooperation with Bilibili Station Knowledge Sharing UP Master [CRISPR Senior Sister]. Welcome to scan the above two-dimensional code and join the [Qizi Plan]!

In August 2023, the "Qizi Plan" for sharing high-quality KO cells in scientific research jointly initiated by CRISPR and Elem Biology was officially released. China Typical Culture Collection Center (CCTCC), Hangzhou Hua 'an Biology and many other units joined the plan to jointly establish quality standards for the domestic gene editing cell industry, establish domestic high-end cell brands, save scientific research funds and build popular science undertakings for gene editing technology.

View All Information

Talent Recruitment

Looking forward to your joining, I hope we can join hands to create a better tomorrow!

Talent Recruitment
< 1 > 跳转到